Biological Correlates To Support A Clinical Role For Tagraxofusp, A Novel Targeted Therapy Directed To Cd123, In Combination With Pomalidomide And Dexamethasone, To Target Plasmacytoid Dendritic Cells In Poor-Risk Patients With Multiple Myeloma.